Andrea Botti
@ausl.re.it
AUSL IRCCS Reggio Emilia
Scopus Publications
- Real-time detection of extravasation events of diagnostic and therapeutic radiopharmaceuticals in oncology
Noemi Cucurachi, Federica Fioroni, Elisa Grassi, Nicola Panico, Laura Verzellesi, et al.
Plos One, 2026
Background Radiopharmaceutical extravasation—when injected activity remains in soft tissue rather than entering the bloodstream—can compromise quantification in positron emission tomography/computed tomography (PET/CT) and, in therapeutic settings, deliver high local radiation doses. These effects may lead to inaccurate Standardized Uptake Value (SUV) measurements, potential misdiagnosis, repeat examinations, and to avoid patient risk. We assessed a simple, real-time approach for detecting extravasation during administration to enable immediate management and quantitative correction. Results Real-time monitoring with portable gamma detectors was applied to 885 diagnostic PET examinations ( 18 F-FDG, 68 Ga-DOTATOC/TATE, 68 Ga-PSMA-11) and 15 administrations of 177 Lu-DOTATATE therapy. In the diagnostic cohort, 53 extravasation events were identified and confirmed on PET images. Analysis of dose-rate–time curves yielded practical thresholds for extravasation detection: Δp in nor = 0.30 and ΔR t = 388 µSv/h. A statistically significant association was observed between SUV correction factors and specific curve parameters, enabling prospective adjustment of SUV before image interpretation. In the therapeutic cohort, one extravasation was observed, with an estimated absorbed self-dose of 11.6 Gy to the affected region. The monitoring enabled timely intervention that limited unnecessary exposure and workflow disruption. Feasibility analyses indicated that, for diagnostic procedures, a single detector can be sufficient for reliable extravasation identification and for deriving SUV correction factors. Conclusions A real-time, detector-based strategy can identify radiopharmaceutical extravasation during injection, support immediate mitigation, and preserve diagnostic accuracy by allowing early SUV correction. In therapeutic applications, it can reduce risk by prompting management of rare but consequential events. The operational simplicity, low cost, and effectiveness demonstrated across both diagnostic and therapeutic scenarios support integration of this approach into routine clinical practice, with the added practicality that a single detector appears adequate for diagnostic workflows. - A Pipeline for MRI-Guided dose painting by number radiation Therapy: GLIORAD − a phase I-II clinical trial in recurrent glioblastoma
Andrea Botti, Roberto Sghedoni, Matteo Orlandi, Giulia Paolani, Patrizia Ciammella, et al.
Physica Medica, 2026 - Low-Dose Radiotherapy for Primary Cutaneous Indolent B-Cell Lymphomas: a Multicenter Retrospective Study
E Alì, G Simontacchi, M Levis, F Iori, S Gambara, et al.
Radiotherapy and Oncology, 2026 - Using HistoQC to predict disagreement on human epidermal growth factor receptor 2 (HER2) assessment
Laura Verzellesi, Moira Ragazzi, Andrea Botti, Giacomo Santandrea, Andrew Janowczyk, et al.
Physica Medica, 2025 - Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)
P. Ciammella, F. Iori, P. Borghetti, M. Galaverni, E. Alì, et al.
Lung Cancer, 2025 - Spatially Fractionated Radiation Therapy for Palliation in Patients With Large Cancers: A Retrospective Study
Federico Iori, Valeria Trojani, Alice Zamagni, Patrizia Ciammella, Mauro Iori, et al.
Advances in Radiation Oncology, 2025 - Refining Treatment Planning in STereotactic Arrhythmia Radioablation: Benchmark Results and Consensus Statement From the STOPSTORM.eu Consortium
Valeria Trojani, Melanie Grehn, Andrea Botti, Brian Balgobind, Alessandro Savini, et al.
International Journal of Radiation Oncology Biology Physics, 2025 - LatticeOpt: An automatic tool for planning optimisation of spatially fractionated stereotactic body radiotherapy
Andrea Botti, Domenico Finocchiaro, Nicola Panico, Valeria Trojani, Giulia Paolani, et al.
Physica Medica, 2024 - CCL18, CHI3L1, ANG2, IL-6 systemic levels are associated with the extent of lung damage and radiomic features in SARS-CoV-2 infection
Ilaria Ferrigno, Laura Verzellesi, Marta Ottone, Martina Bonacini, Alessandro Rossi, et al.
Inflammation Research, 2024 - Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis
Patrizia Ciammella, Salvatore Cozzi, Paolo Borghetti, Marco Galaverni, Valerio Nardone, et al.
Frontiers in Oncology, 2024
BackgroundChemoradiation therapy (CRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell death 1 (PD1) axis inhibitors with radiotherapy are in development for patients with LA-NSCLC. However, the effect of CRT on tumor cells programmed cell death ligand-1 (PD-L1) expression is unknown.MethodsIn this multicentric retrospective study, we analyzed paired NSCLC specimens that had been obtained pre- and post-CRT. PD-L1 expression on tumor cells was studied by immunohistochemistry. The purpose of this study was to evaluate the feasibility, risk of complications, and clinical relevance of performing re-biopsy after CRT in patients with PD-L1 negative LA-NSCLC.ResultsOverall, 31 patients from 6 centers with PD-L1 negative LA-NSCLC were analyzed. The percentage of tumor cells with PD-L1 expression significantly increased between pre- and post-CRT specimens in 14 patients (45%). Nine patients had unchanged PD-L1 expression after CRT, in five patients the rebiopsy material was insufficient for PD-L1 analysis and in two patients no tumor cells at rebiopsy were found. The post-rebiopsy complication rate was very low (6%). All patients with positive PD-L1 re-biopsy received Durvalumab maintenance after CRT, except one patient who had a long hospitalization for tuberculosis reactivation. Median PFS of patients with unchanged or increased PD-L1 expression was 10 and 16.9 months, respectively.ConclusionCRT administration can induce PD-L1 expression in a considerable fraction of PD-L1 negative patients at baseline, allowing them receiving the maintenance Durvalumab in Europe. Hence, after a definitive CRT, PD-L1 redetermination should be considered in patients with LA-NSCLC PD-L1 negative, to have a better selection of maintenance Durvalumab candidates. - Safety injections of nuclear medicine radiotracers: towards a new modality for a real-time detection of extravasation events and 18F-FDG SUV data correction
Mauro Iori, Elisa Grassi, Lorenzo Piergallini, Greta Meglioli, Andrea Botti, et al.
Ejnmmi Physics, 2023 - Machine and Deep Learning Algorithms for COVID-19 Mortality Prediction Using Clinical and Radiomic Features
Laura Verzellesi, Andrea Botti, Marco Bertolini, Valeria Trojani, Gianluca Carlini, et al.
Electronics Switzerland, 2023 - A Monte Carlo Calibration Approach For A Dual-Energy CT System
LORENZO ISOLAN, ANDREA FORMOSI, FRANCESCO TEODORI, ANDREA BOTTI, MARCO BERTOLINI, et al.
Journal of Mechanics in Medicine and Biology, 2023 - Good clinical practice and the use of hypofractionation radiation schedules as weapons to reduce the risk of COVID-19 infections in radiation oncology unit: A mono-institutional experience
Salvatore Cozzi, MariaPaola Ruggieri, Lilia Bardoscia, Masoumeh Najafi, Gladys Blandino, et al.
Journal of Cancer Research and Therapeutics, 2023 - Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes
Salvatore Cozzi, Sebastiano Finocchi Ghersi, Lilia Bardoscia, Masoumeh Najafi, Gladys Blandino, et al.
Strahlentherapie Und Onkologie, 2023 - Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients
SALVATORE COZZI, MARIA PAOLA RUGGIERI, EMANUELE ALÌ, SEBASTIANO FINOCCHI GHERSI, FEDERICA VIGO, et al.
In Vivo, 2023 - Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review
Masoumeh Najafi, Amin Jahanbakhshi, Sebastiano Finocchi Ghersi, Lucia Giaccherini, Andrea Botti, et al.
Brain Sciences, 2023 - Thoracic Radiotherapy in Extensive Disease Small Cell Lung Cancer: Multicenter Prospective Observational TRENDS Study
Salvatore Cozzi, Alessio Bruni, Maria Paola Ruggieri, Paolo Borghetti, Vieri Scotti, et al.
Cancers, 2023 - Ductal prostate cancer: Clinical features and outcomes from a multicenter retrospective analysis and overview of the current literature
Salvatore Cozzi, Lilia Bardoscia, Masoumeh Najafi, Sefik Igdem, Luca Triggiani, et al.
Current Urology, 2022 - How a very large sarcomatoid lung cancer was efficiently managed with lattice radiation therapy: a case report
Federico Iori, Andrea Botti, Patrizia Ciammella, Salvatore Cozzi, Matteo Orlandi, et al.
Annals of Palliative Medicine, 2022 - The Use of Cardiac Stereotactic Radiation Therapy (SBRT) to Manage Ventricular Tachycardia: A Case Report, Review of the Literature and Technical Notes
Salvatore Cozzi, Nicola Bottoni, Andrea Botti, Valeria Trojani, Emanuele Alì, et al.
Journal of Personalized Medicine, 2022 - Evaluating the Quality of Patient-Specific Deformable Image Registration in Adaptive Radiotherapy Using a Digitally Enhanced Head and Neck Phantom
Elisabetta Cagni, Andrea Botti, Matteo Orlandi, Marco Galaverni, Cinzia Iotti, et al.
Applied Sciences Switzerland, 2022 - Safety of Inhomogeneous Dose Distribution IMRT for High-Grade Glioma Reirradiation: A Prospective Phase I/II Trial (GLIORAD TRIAL)
Patrizia Ciammella, Salvatore Cozzi, Andrea Botti, Lucia Giaccherini, Roberto Sghedoni, et al.
Cancers, 2022 - Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer: An investigation of 117 pelvic lymph nodes
Salvatore Cozzi, Andrea Botti, Giorgia Timon, Gladys Blandino, Masoumeh Najafi, et al.
Strahlentherapie Und Onkologie, 2022 - Novel Harmonization Method for Multi-Centric Radiomic Studies in Non-Small Cell Lung Cancer
Marco Bertolini, Valeria Trojani, Andrea Botti, Noemi Cucurachi, Marco Galaverni, et al.
Current Oncology, 2022
